Low ER+ Breast Cancer
The DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Estrogen receptor (ER) level can be semiquantified by immunohistochemistry (IHC) using the H-score. The score, given as the sum of the percent staining multiplied by the intensity level, ranges from 0 to 300. METHODS: Forty-nine ER+/HER2- invasive tumors with low ER expression (H-scores of 1-100, representing approximately 5% of all tumors) were studied for various morphologic parameters, progesterone receptor (PR), and Ki-67 IHC. RESULTS: Eighteen of 49 patients received neoadjuvant chemotherapy. The morphologic analysis showed that these tumors are often grade 3 and frequently demonstrate a sheet-like growth pattern, an intratumoral lymphocytic inflammatory infiltrate, and necrosis. Eighty percent of tumors showed a Ki-67 proliferation index of more than 50%, and 94% were PR-. Of the 18 patients who received neoadjuvant chemotherapy, six (33%) achieved pathologic complete response. CONCLUSIONS: The low ER+/HER2- cases have morphologic features and a response to the chemotherapy rate that are more similar to triple-negative tumors than the usual type of ER+ tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They may share morphological (high grade, poor differentiation)92 and biological features93 , 94 with TNBC and experience a similarly poor survival.95 , 96”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [92]
Citations
Cites
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundRace, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundKi67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundPhenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
BackgroundCuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739 · cited 1×
“0) Positive nodal status,b excluding isolated tumor cells 14 (35) Nottingham grade Grade 2 4 (8) Grade 3 45 (92) PR Positive 3 (6) H-scores on PR+ cases, mean/median (range) 36/35 (3-70) HER2 status IHC score 0 or 1+ 28 (57) IHC score 2+, FISH not amplified 17 (35) IHC score 2+, FISH equivocal 4 (8) Ki-67 labeling ind…”
Background
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
“Complicating the understanding of low ER–expressing cancers are data indicating that these cancers are a heterogeneous group but often have clinical outcomes and biologic/molecular profiles that are often more similar to those of ER-negative cancers.(91-97,106) However, none of these retrospective and nonrandomized st…”
BackgroundResult5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0904-sa · Cited by 374
PARP inhibition in breast cancer: progress made and future hopes
Tung, N., & Garber, J. E. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00411-3 · Cited by 164
Metadata
- Authors
- Gloyeske, N. C., Dabbs, D. J., & Bhargava, R.
- Affiliations
- Magee-Womens Hospital (US)
- Venue
- American Journal of Clinical Pathology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-01
- Volume
- 141
- Issue
- 5
- Pages
- 697-701
- ISSN
- 0002-9173 (ISSN-L)
- 1943-7722
- OpenAlex
- W2276292796
- Cited by
- 63
- References
- 25
- Citations by year
- 2025: 6 · 2024: 2 · 2023: 13 · 2022: 9 · 2021: 6 · 2020: 8 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 5
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Clinical Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- ER+/HER2- breast cancer, H-score, tumor morphology, Ki-67 proliferation index, progesterone receptor, neoadjuvant chemotherapy, pathological complete response, triple-negative breast cancer, tumor necrosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Immunohistochemistry, Middle Aged, Prognosis, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Tumor, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low ER+ Breast Cancer. https://app.cochat.ai/papers/10.1309/ajcp34cysatwfdpq
- The paper
- Gloyeske, N. C., Dabbs, D. J., & Bhargava, R. (2014). Low ER+ Breast Cancer. American Journal of Clinical Pathology. https://doi.org/10.1309/ajcp34cysatwfdpq
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.